John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.